FDA's Recent Regulation on the Use of Social Media
About the Course
Social media platforms present significant regulatory and operational challenges for organizations promoting FDA-regulated drug products and medical devices. Public-facing communications must balance benefit and risk information while adapting to character limitations, third-party interactions, and evolving regulatory expectations. Inconsistent handling of promotional content or misinformation can create compliance exposure, particularly when multiple business functions contribute to product messaging and digital communication activities.
The course addresses FDA guidance governing the use of social media within regulated environments and outlines practical considerations for developing compliant policies, procedures, and communication strategies. Attention is given to managing independent third-party content, handling space-restricted platforms, and understanding pending regulatory action from the US Congress. The material is particularly relevant for organizations operating within life sciences, tobacco, and other FDA-regulated sectors where product presentation, electronic systems, and compliance responsibilities frequently intersect. These requirements continue to affect marketing, regulatory, clinical, and technology functions involved in regulated communications.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Commonly Asked Questions About This Subject
How should organizations determine when social media activity creates regulatory responsibility for company oversight?
Social media activity creates regulatory responsibility when the organization has sufficient control, influence, or involvement in the creation, approval, modification, or distribution of product-related content. Decisions about oversight should be based on documented governance rather than assumptions about who originally posted the information.
Regulatory concerns often arise when business functions interact with online content in ways that blur the distinction between independent user activity and company-sponsored communication. Sharing, editing, endorsing, or selectively responding to product-related posts can create questions about whether the organization accepted responsibility for the resulting message.
Documentation becomes particularly important when internal teams decide not to intervene in discussions involving inaccurate or incomplete information. Reviewers may expect evidence showing that the decision was evaluated using established criteria rather than informal judgment.
A defensible governance process defines when social media activity requires regulatory review, identifies who has authority to make those decisions, and preserves the rationale supporting actions taken or intentionally not taken.
What documentation practices strengthen the defensibility of social media compliance decisions during regulatory review?
Documentation should explain why communication decisions were made, not simply preserve copies of published content. Reviewers frequently evaluate whether product-related posts, approvals, revisions, escalations, and monitoring activities demonstrate consistent application of internal policies throughout the communication lifecycle.
Inspection questions often increase when organizations cannot reconstruct how a particular message was reviewed, who approved it, what supporting evidence was considered, or why specific compliance decisions were reached. Missing decision records can make otherwise reasonable actions difficult to defend months after publication.
Records should also document how evolving scientific information, labeling changes, or regulatory developments affected ongoing communication decisions. Preserving only the final version of content provides limited evidence if the reasoning behind revisions cannot be explained.
A well maintained documentation system allows an independent reviewer to understand how regulatory, medical, legal, and commercial considerations were evaluated before content reached the public, supporting greater confidence in the organization's governance process.
How should organizations manage conflicting internal opinions about the regulatory acceptability of social media content?
Conflicting opinions should be resolved through a documented decision process that evaluates available evidence against established regulatory principles rather than relying on organizational hierarchy or business urgency. Differences of opinion are expected when promotional, medical, legal, and regulatory functions evaluate the same communication from different perspectives.
Review concerns increase when disagreements are resolved informally without documenting the technical basis for the final decision. If questions arise later, reviewers often examine whether alternative viewpoints were considered and whether the selected approach was supported by objective reasoning.
Well documented discussions strengthen regulatory credibility because they demonstrate that significant communication decisions received appropriate multidisciplinary evaluation before publication. Records should identify the issues debated, the evidence reviewed, and the justification supporting the final outcome.
A structured governance process provides stronger support than unanimous agreement. Regulators are generally more interested in the quality of the decision making process than whether every stakeholder initially reached the same conclusion.
What makes social media compliance decisions difficult to defend during an FDA inspection or enforcement review?
Social media compliance decisions become difficult to defend when organizations cannot demonstrate consistent application of their own policies across similar situations. Reviewers frequently compare how different platforms, products, campaigns, and public interactions were handled to determine whether regulatory oversight remained objective and predictable.
Inspection concerns often emerge when comparable content receives different levels of review or when corrective actions appear inconsistent without documented justification. Inconsistency may suggest that compliance decisions depend on individual judgment rather than an established governance framework.
Supporting records should also explain how significant communication risks were identified, evaluated, and monitored after publication. Without that documentation, reviewers may question whether oversight continued beyond the initial approval process.
A defensible compliance program demonstrates that communication decisions are supported by objective criteria, documented rationale, and repeatable review practices that remain consistent regardless of the platform, product, or internal business priorities.
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


